Company intelligence / Profile preview

Nanordica Medical

Ownership: Private
Employees: ~15
Development stage: Other

Overview

Nanordica Medical’s advanced antibacterial wound dressing has demonstrated promising results in early studies. A multicenter clinical trial involving 170 patients with diabetic foot ulcers is planned to start in Q2 2024 to further validate efficacy and safety. The company’s first veterinary product launched in 2023, while the human product is expected to launch in 2025.

Therapeutic areas: DermatologyEndocrinologyInfectious DiseasesOther
Modalities: DeviceNanoparticleHydrogel-based drug delivery therapy (silk nanofiber wound dressing with embedded nanoparticles)
Industry: Therapeutic Medical Devices

Partnerships

Planned multicenter clinical trial coordinated by Prof. Dr. José Luis Lázaro Martínez at European Wound Management Associationmember of Tehnopol HealthTech Community

Beyond the preview

Go deeper on Nanordica Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nanordica Medical.

Explore the full profile